SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to a significant price drop, sparking intense debate among investors regarding potential insider selling after a lock-up period expired. The community is actively analyzing trading volume and support levels, with some viewing the dip as a buying opportunity, while others express concern about continued selling pressure. Amidst the volatility, there's speculation about a potential short squeeze and comparisons to similar situations with other trading platforms.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions of a potential bubble in the quantum computing sector and scrutiny of its high valuation relative to revenue. Community chatter includes debate between bullish and bearish viewpoints, with some highlighting insider selling and concerns about future dilution, while others remain optimistic about the long-term potential of quantum computing. Technical analysis and pattern observations are also prominent in the conversation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate whether the stock is overvalued and due for a pullback, or if it still has room to run based on the future potential of quantum computing. Bears cite concerns over financials and potential offerings, while bulls point to the company's advancements and growing interest in the sector. Discussions also involve comparing RGTI to other quantum computing stocks and broader market trends.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors react to news of a significant deal with OpenAI, including OpenAI potentially acquiring a substantial stake in AMD. The community buzz centers on the implications of this partnership for AMD's position in the AI chip market, with some anticipating significant growth and others cautioning about overvaluation. Bullish sentiment is strong, with many seeing AMD as a key player in the future of AI.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amidst community discussion around a recent private placement and its potential impact, with debates focusing on dilution versus the company's increased financial strength. Some traders are pointing to technical indicators and anticipating a short squeeze, while others express concerns about the company's fundamentals and an ongoing SEC investigation; the stock's movement is also discussed in the context of the broader quantum computing sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending amid fluctuating sentiments, with community members debating whether it's experiencing a classic panic sell-off or a bear trap. Some traders are suggesting taking profits, while others urge holding for a potential surge, emphasizing the company's long-term prospects in the quantum computing sector. The conversation includes discussion of a newly launched ETF that shorts QBTS.

Fitell Corp. engages in the business of selling gym and fitness equipment. It also offers turnkey solution for personal training studios and commercial gym chains. Its brands include Muscle Motion, Rapid Motion, and FleetX. The company was founded in 2007 and is headquartered in Sydney, Australia.

Fitell Corp - Ordinary Shares - Class A

Fitell Corp

FTEL is trending due to high volume and community discussion around its low float and potential for a significant price increase. The company's recent investment in a Solana treasury and Nasdaq extension are being viewed as positive catalysts. Community members are actively discussing potential price targets and the possibility of a short squeeze.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its potential for a short squeeze, driven by high short interest and unusual options activity. Some investors are optimistic about the company's AI-driven drug discovery platform, particularly its use case in healthcare, and potential catalysts. Others remain cautious, pointing to insider selling and cash burn as concerns.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

American Rebel Holdings is trending due to an announced 1-for-20 reverse stock split with a unique "round lot protection" provision guaranteeing those holding at least 100 shares will maintain that amount post-split, sparking community debate and speculative trading strategies. Traders are actively discussing the potential for a short squeeze and the stock's volatile history, while also evaluating the implications of insider selling and a recent resolution of debt with Bank of America. The community is weighing the risks and potential rewards of this situation.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending as community members discuss the potential impact of the company's focus on building a TON token treasury and its integration with the Telegram ecosystem. Some traders are drawing comparisons to other recent low-float runners and anticipating a significant price movement. However, other investors caution about potential dilution and the company's shift in focus from biotech to crypto.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day, reflecting a -6.98% change compared to its last close.

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $61.67, marking a +2.24% move from the previous day.

CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU

CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.07, marking a -3.46% move from the previous day.

Vertex Plunges Around 24% in Six Months: How to Play the Stock

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?

Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$77.19
Prev Close	$70.62
Open	$71.36
Dividend Yield	0.00%
50-Day Moving Average	$58.18
Beta	1.56
Avg. Volume	2.37M
PE Ratio	-13.02

52-Week High	$73.95
52-Week Low	$30.04
Market Capitalization	$6.42B
EPS (Annual)	-$4.34
Price to Book	3.65
Revenue Per Employee	$94,946.57
Enterprise Value/EBITDA	N/A

CRSP
CRISPR Therapeutics AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRSP News

CRSP CRISPR Therapeutics AG